Yuan J, Wang M, Pan Y, et al
Liraglutide (Victoza) followed in 2010, semaglutide (Ozempic) in 2017, oral semaglutide (Rybelsus) in 2019, semaglutide for weight loss (Wegovy) in 2021, and the first GIP/GLP-1 dual agonist tirzepatide (Mounjaro) in 2022 with its weight-loss sibling Zepbound in 2023
What to test and rule out before you chase LL-37 A peptide cannot fix what you have not named
Most people have no symptoms, but if it grows too much, it can damage the lining
To understand how HPLC purity is used in peptide analysis, including chromatograms, LC-MS testing and Certificate of Analysis documentation, read our educational guide
Community and peer support help many people navigate switching challenges